Ser157
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser157  -  Telethonin (human)

Site Information
GALRRsLsRSMsQEA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448693

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 3 , 4 ) , HEK293T (epithelial) ( 1 ) , myocyte-heart ( 2 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 1 )
Kinases, in vitro:
CAMK2A (human) ( 2 ) , GSK3B (human) ( 1 ) , PRKD1 (human) ( 2 )
Treatments:
CHIR99021 ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on Telethonin:
protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 2 )

References 

1

Wirianto M, et al. (2020) The GSK-3β-FBXL21 Axis Contributes to Circadian TCAP Degradation and Skeletal Muscle Function. Cell Rep 32, 108140
32937135   Curated Info

2

Candasamy AJ, et al. (2014) Phosphoregulation of the Titin-cap Protein Telethonin in Cardiac Myocytes. J Biol Chem 289, 1282-93
24280220   Curated Info

3

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

4

Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65
19764811   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.